Prodrug-loaded micelles targeting articular cavity reactive oxygen species for rheumatoid arthritis treatment
Source abstract
Abstract
Oxidative stress plays an important role in the pathogenesis of rheumatoid arthritis (RA). Excessive reactive oxygen species (ROS) activate the NLR family pyrin domain containing 3 (NLRP3) inflammasome, release multiple inflammatory mediators, stimulate macrophage polarization, and exacerbate the inflammatory response. In response to the pathological features of RA, we designed a dihydroartemisinin (DHA)-ROS sensitive prodrug loaded into carriers of Soluplus and Vitamin E polyethylene glycol succinate (TPGS) using a thin film hydration to expect that the nano-micelles could target for delivery to the inflammation site due to extravasation through leaky vasculature and subsequent inflammatory cell-mediated sequestration (ELVIS) effects, and the higher ROS level in articular cavity resulting in the breaking of ROS sensitive bonds and the release of anti-inflammatory DHA and antioxidant cinnamaldehyde (CA), avoiding the instability of DHA and CA circulating in the body. In addition, prodrug-carrying nanomicelles (DHA∼CA@NM) promoted the polarization of M1 to M2 macrophages, which exerted a series of anti-inflammatory effects. Intravenously injected DHA∼CA@NM could accumulate at inflamed joints of CIA rats, attenuate joint damage and bone erosion, and inhibit synovial hyperplasia and formation of pannus, thus alleviating joint inflammation and displaying high biosafety. The protective mechanism of DHA∼CA@NM may be related to the inhibition of NLRP3 inflammasome, which has the potential to be developed as a safe and effective nano-formulation for the treatment of RA. A ROS-sensitive prodrug loaded into Soluplus and TPGS carriers. Higher ROS levels in the rheumatoid joint cavity lead to the breaking of ROS-sensitive bonds, releasing anti-inflammatory DHA and antioxidant CA, which synergistically modulate NLR family pyrin domain containing 3 (NLRP3) inflammasome and macrophage repolarization for effective treatment of rheumatoid arthritis. • ROS-responsive micelles enable precise DHA/CA delivery to inflamed joints. • Dual-drug micelles synergistically suppress M1 macrophage polarization. • DHA∼CA@NM inhibits NLRP3 inflammasome via scavenging ROS. • DHA∼CA@NM alleviates joint inflammation and joint damage in RA.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Rheumatoid Arthritis Research and Therapies · Inflammasome and immune disorders · Immune cells in cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (56)
Show source-provided references
1. Diagnosis and management of rheumatoid arthritis: a review10.1001/jama.2018.13103 ↗
2. Rheumatoid arthritis10.1038/nrdp.2018.1 ↗
3. Caffeic acid modified nanomicelles inhibit articular cartilage deterioration and reduce disease severity in experimental inflammatory arthritis10.1021/acsnano.2c07027 ↗
4. Hybrid micelles containing methotrexate-conjugated polymer and co-loaded with microRNA-124 for rheumatoid arthritis therapy10.7150/thno.32268 ↗
5. Clinical effect and biological mechanism of exercise for rheumatoid arthritis: a mini review
6. Therapeutic advances in rheumatoid arthritis10.1136/bmj-2022-070856 ↗
7. ROS-responsive berberine polymeric micelles effectively suppressed the inflammation of rheumatoid arthritis by targeting mitochondria10.1007/s40820-020-0410-x ↗
8. Emerging nanotherapeutics alleviating rheumatoid arthritis by readjusting the seeds and soils10.1016/j.jconrel.2022.04.001 ↗
9. Drug in therapeutic polymer: sinomenine-loaded oxidation-responsive polymeric nanoparticles for rheumatoid arthritis treatment10.1021/acsami.3c10562 ↗
10. Inflammation-targeted celastrol nanodrug attenuates collagen-induced arthritis through NF-κB and Notch1 pathways10.1021/acs.nanolett.0c03279 ↗
11. Ganoderma lucidum polysaccharide peptide (GLPP) attenuates rheumatic arthritis in rats through inactivating NF-κB and MAPK signaling pathways10.1016/j.phymed.2023.155010 ↗
12. Multifunctional nanoparticles of sinomenine hydrochloride for treat-to-target therapy of rheumatoid arthritis via modulation of proinflammatory cytokines10.1016/j.jconrel.2022.05.016 ↗
13. Development of pH-sensitive dextran-based methotrexate nanodrug for rheumatoid arthritis therapy through inhibition of JAK-STAT pathways10.1016/j.ijpharm.2022.121874 ↗
14. Delivery of germacrone (GER) using macrophages-targeted polymeric nanoparticles and its application in rheumatoid arthritis10.1080/10717544.2022.2044936 ↗
15. Dextran sulfate-based MMP-2 enzyme-sensitive SR-A receptor targeting nanomicelles for the treatment of rheumatoid arthritis10.1080/10717544.2022.2032482 ↗
16. Dihydroartemisinin derivative DC32 attenuates collagen-induced arthritis in mice by restoring the Treg/Th17 balance and inhibiting synovitis through down-regulation of IL-610.1016/j.intimp.2018.10.015 ↗
17. The immunosuppressive activity of artemisinin-type drugs towards inflammatory and autoimmune diseases10.1002/med.21842 ↗
18. Artemisinins: promising drug candidates for the treatment of autoimmune diseases10.1002/med.22001 ↗
19. Guo · 2024 · vol. 7 · 459
20. Suppression of NLRP3 inflammasome by Dihydroarteannuin via the HIF-1α and JAK3/STAT3 signaling pathway contributes to attenuation of collagen-induced arthritis in mice
21. Reactive oxygen species-responsive polymeric prodrug nanoparticles for selective and effective treatment of inflammatory diseases
22. Glucocorticoid-loaded pH/ROS dual-responsive nanoparticles alleviate joint destruction by downregulating the NF-κB signaling pathway10.1016/j.actbio.2023.04.012 ↗
23. Metal-organic framework-encapsulated dihydroartemisinin nanoparticles induces apoptotic cell death in ovarian cancer by blocking ROMO1-mediated ROS production10.1186/s12951-023-01959-3 ↗
24. Encapsulation of cinnamaldehyde: an insight on delivery systems and food applications10.1080/10408398.2021.1977236 ↗
25. Triptolide and l-ascorbate palmitate co-loaded micelles for combination therapy of rheumatoid arthritis and side effect attenuation10.1080/10717544.2022.2115162 ↗
26. Cinnamaldehyde-based poly(thioacetal): a ROS-awakened self-amplifying degradable polymer for enhanced cancer immunotherapy10.1016/j.biomaterials.2022.121795 ↗
27. Dendrobium huoshanense stem polysaccharide ameliorates rheumatoid arthritis in mice via inhibition of inflammatory signaling pathways10.1016/j.carbpol.2021.117657 ↗
28. Targeted silver nanoparticles for rheumatoid arthritis therapy via macrophage apoptosis and Re-polarization10.1016/j.biomaterials.2020.120390 ↗
29. Combination of magnesium ions and vitamin C alleviates synovitis and osteophyte formation in osteoarthritis of mice
30. Escinosome thermosensitive gel optimizes efficacy of CAI-CORM in a rat model of rheumatoid arthritis10.1016/j.jconrel.2023.04.045 ↗
31. Prodrug nanomedicine for synovium targeted therapy of inflammatory arthritis: insights from animal model and human synovial joint fluid10.1002/adhm.202401936 ↗
32. Targeting lymph nodes for systemic immunosuppression using Cell-Free-DNA-Scavenging and cGAS-Inhibiting nanomedicine-in-hydrogel for Rheumatoid arthritis immunotherapy10.1002/advs.202302575 ↗
33. Engineering prodrug nanomedicine for cancer immunotherapy10.1002/advs.202002365 ↗
34. Macrophage membrane-reversibly cloaked nanotherapeutics for the anti-inflammatory and antioxidant treatment of rheumatoid arthritis10.1002/smtd.202300667 ↗
35. Attempt to construct an In vitro model of enhancement of macrophage phagocytosis via continuous administration of LPS10.21873/anticanres.14472 ↗
36. The cellular immunotherapy of integrated photothermal anti-oxidation Pd-Se nanoparticles in inhibition of the macrophage inflammatory response in rheumatoid arthritis10.1016/j.apsb.2021.02.021 ↗
37. Ultrasmall iron-quercetin metal natural product nanocomplex with antioxidant and macrophage regulation in rheumatoid arthritis10.1016/j.apsb.2022.11.020 ↗
38. Ingenious synergy of a pathology-specific biomimetic multifunctional nanoplatform for targeted therapy in Rheumatoid arthritis
39. Targeted delivery of low-dose dexamethasone using PCL-PEG micelles for effective treatment of rheumatoid arthritis10.1016/j.jconrel.2016.03.035 ↗
40. Enhanced therapeutic effect of RGD-Modified polymeric micelles loaded with low-dose methotrexate and nimesulide on rheumatoid arthritis10.7150/thno.30418 ↗
41. Carrier-free poly(glycyrrhetinic acid)-facilitated celastrol-loaded nanoparticle for high-efficiency low-toxicity treatment of rheumatoid arthritis10.1016/j.matdes.2024.112951 ↗
42. Nanoparticulate DNA scavenger loading methotrexate targets articular inflammation to enhance rheumatoid arthritis treatment10.1016/j.biomaterials.2022.121594 ↗
43. Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases10.1038/s41584-024-01120-w ↗
44. Methotrexate-loaded nanoparticles ameliorate experimental model of autoimmune arthritis by regulating the balance of interleukin-17-producing T cells and regulatory T cells10.1186/s12967-022-03267-0 ↗
45. Formulation of a dual drug-loaded nanoparticulate co-delivery hydrogel system and its validation in rheumatoid arthritis animal model10.1080/10717544.2023.2184307 ↗
46. Ferrihydrite nanoparticles alleviate Rheumatoid arthritis by nanocatalytic antioxidation and oxygenation10.1021/acs.nanolett.3c02743 ↗
47. An ROS-responsive artesunate prodrug nanosystem co-delivers dexamethasone for rheumatoid arthritis treatment through the HIF-1α/NF-κB cascade regulation of ROS scavenging and macrophage repolarization10.1016/j.actbio.2022.08.054 ↗
48. Neutrophil-Mimetic, ROS responsive, and oxygen generating nanovesicles for targeted interventions of refractory rheumatoid arthritis
49. Macrophage targeted triptolide micelles capable of cGAS-STING pathway inhibition for rheumatoid arthritis treatment10.1080/1061186X.2022.2070173 ↗
50. Dual-Stimuli responsive polymeric micelles for the effective treatment of rheumatoid arthritis10.1021/acsami.1c04953 ↗
51. Role of the NLRP3 inflammasome in autoimmune diseases
52. Mechanisms of NLRP3 inflammasome in rheumatoid arthritis and osteoarthritis and the effects of traditional Chinese medicine10.1016/j.jep.2023.117432 ↗
53. NLRP3 inflammasome and its role in autoimmune diseases: a promising therapeutic target
54. NLRP3: a promising therapeutic target for autoimmune diseases10.1016/j.autrev.2018.01.020 ↗
55. Therapeutic potential of targeting the NLRP3 inflammasome in rheumatoid arthritis10.1007/s10753-023-01795-5 ↗
56. ROS-mediated liposomal dexamethasone: a new FA-targeted nanoformulation to combat rheumatoid arthritis via inhibiting iRhom2/TNF-α/BAFF pathways10.1039/D1NR05518F ↗